HER2-ultralow Metastatic Breast Cancer Companion Diagnostic Approved by FDA
Roche’s PATHWAY anti-HER2/neu (4B5) test has received FDA approval to ID patients with HR-positive, HER2-ultralow metastatic breast cancer.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
